PAULA ROTHER: Open Payments
NPI 1780184754 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,741 in 148 payments from 16 companies in 2025. Trend: 2023 $1,752 · 2024 $1,947 · 2025 $2,741
Food & beverage: $2,741
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $606 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $501 |
| Otsuka America Pharmaceutical, Inc. | 12 | $236 |
| Alkermes, Inc. | 13 | $231 |
| Janssen Pharmaceuticals, Inc | 13 | $209 |
| Teva Pharmaceuticals USA, Inc. | 8 | $185 |
| Neurocrine BioSciences, Inc. | 7 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $122 |
| Supernus Pharmaceuticals, Inc. | 6 | $112 |
| Corium, LLC | 3 | $107 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, INGREZZA, TRINTELLIX, AUSTEDO XR, ARISTADA.
Industry payments across OK — which companies pay providers there.
